Interferon-Gamma Increases the Ratio of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 in Peripheral Monocytes from Patients with Coronary Artery Disease

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Springall, Rashidi ^a   Amezcua Guerra, Luis M ^a   Gonzalez Pacheco, Hector ^a   Furuzawa Carballeda, Janette ^b   Gomez Garcia, Lorena ^a   Marquez Velasco, Ricardo ^a   Mejía Domínguez, Ana María ^a   Cossío Aranda, Jorge ^a   Martínez Sánchez, Carlos ^a   Bojalil, Rafael ^a,c  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD DONOR; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; HUMAN; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUPERNATANT; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MONOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84881530089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072291     Document Type: Article

References (27)

1. Hanson MA, Fareed MT, Argenio SL, Agunwamba AO, Hanson TR, (2013) Coronary artery disease. Prim Care 40: 1-16. doi:10.1016/j.pop.2012.12.001. PubMed: 23402459.
2. Sánchez-Diaz CJ, García-Badillo E, Sánchez-Ramírez CJ, Juárez U, Martínez-Sánchez C, (2012) Clinical characteristics, process of care and outcomes among Mexican, Hispanic and non-Hispanic white patients presenting with non-ST elevation acute coronary syndromes: Data from RENASICA and CRUSADE registries. Arch Cardiol Mex 82: 14-21. PubMed: 22452861.
3. Zhou J, Chew M, Ravn HB, Falk E, (1999) Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl 230: 3-11. PubMed: 10389196.
4. Siriwardena AN, (2012) Increasing evidence that influenza is a trigger for cardiovascular disease. J Infect Dis 206: 1636-1638. doi:10.1093/infdis/jis598. PubMed: 23048169.
5. Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo SV, et al. (2011) Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis 203: 1710-1718. doi:10.1093/infdis/jir171. PubMed: 21606529.
6. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351: 2611-2618. doi:10.1056/NEJMoa041747. PubMed: 15602021.
7. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 206: 1652-1659. doi:10.1093/infdis/jis597. PubMed: 23048170.
8. Werba JP, Veglia F, Amato M, Baldassarre D, Massironi P, et al. (2008) Patients with a history of stable or unstable coronary heart disease have different acute phase responses to an inflammatory stimulus. Atherosclerosis 196: 835-840. doi:10.1016/j.atherosclerosis.2007.01.033. PubMed: 17335831.
9. Zhang L, Liao MF, Tian L, Zou SL, Lu QS, et al. (2011) Overexpression of interleukin-1β and interferon-γ in type I thoracic aortic dissections and ascending thoracic aortic aneurysms: possible correlation with matrix metalloproteinase-9 expression and apoptosis of aortic media cells. Eur J Cardiothorac Surg 40: 17-22. doi:10.1016/j.ejcts.2010.09.019. PubMed: 21349736.
10. Bench TJ, Jeremias A, Brown DL, (2011) Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res 64: 561-566. doi:10.1016/j.phrs.2011.05.002. PubMed: 21624471.
11. Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, et al. (2008) Atherosclerotic plaque stability--what determines the fate of a plaque? Prog Cardiovasc dis 51: 183-194.
12. Brunner S, Kim JO, Methe H, (2010) Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol 105: 429-434. doi:10.1016/j.amjcard.2009.10.013. PubMed: 20152234.
13. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, et al. (2001) American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38: 2114-2130. doi:10.1016/S0735-1097(01)01702-8. PubMed: 11738323.
14. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG, (1990) Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest 86: 1204-1210. doi:10.1172/JCI114826. PubMed: 2170447.
15. Pedersen ER, Midttun Ø, Ueland PM, Schartum-Hansen H, Seifert R, et al. (2011) Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 31: 698-704. doi:10.1161/ATVBAHA.110.219329. PubMed: 21183733.
16. McLaren JE, Ramji DP, (2009) Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 20: 125-135. doi:10.1016/j.cytogfr.2008.11.003. PubMed: 19041276.
17. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, et al. (2011) Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 32: 1730-1735. doi:10.1093/eurheartj/ehr004. PubMed: 21289042.
18. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B, (2004) Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 25: 25-31. doi:10.1016/j.ehj.2003.10.018. PubMed: 14683739.
19. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, et al. (2008) Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 29: 1350-1358. doi:10.1093/eurheartj/ehm581. PubMed: 18187561.
20. Natarajan P, Cannon CP, (2011) Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. Eur Heart J 32: 1701-1703. doi:10.1093/eurheartj/ehr053. PubMed: 21406438.
21. Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, et al. (2006) Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler Thromb Vasc Biol 26: 2351-2358. doi:10.1161/01.ATV.0000239461.87113.0b. PubMed: 16888239.
22. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, et al. (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37: 235-239. PubMed: 16339461.
23. Cheng M, Hashmi S, Mao X, Zeng QT, (2008) Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 24: 385-390. doi:10.1016/S0828-282X(08)70602-0. PubMed: 18464944.
24. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, et al. (2008) Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 29: 2116-2124. doi:10.1093/eurheartj/ehn315. PubMed: 18614523.
25. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, et al. (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28: 711-718. doi:10.1093/eurheartj/ehm003. PubMed: 17339265.
26. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, et al. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096. doi:10.1161/CIRCULATIONAHA.105.573865. PubMed: 16636176.
27. de Oliveira RT, Mamoni RL, Souza JR, Fernandes JL, Rios FJ, et al. (2009) Differential expression of cytokines, chemokines and chemokines receptors in patients with coronary artery disease. Int J Cardiol 136: 17-26. doi:10.1016/j.ijcard.2008.04.009. PubMed: 18617279.